We studied the psychological and biological correlates of hypoactive sexual desire (HSD) in a consecutive series of 428 patients with erectile dysfunction (ED), by using the structured interview SIEDY r . A complete physical examination and a series of biochemical, hormonal, psychometric, and penile vascular tests were also performed. Among the patients studied, 22.8% reported a mild, 12.9% a moderate, and 4.6% a complete loss of sexual interest. Patients reporting HSD showed significantly lower testosterone (T) levels than the rest of the sample, although the prevalence of hypogonadism (To10 nM) was comparable in the two groups. Only a minority (o2%) had severe hyperprolactinemia (4700 mU/l), which, nonetheless, was closely associated with a relevant HSD. Both mental disorders and use of medication interfering with sexual function were significantly associated with HSD, as well as depressive and anxiety symptoms. HSD patients showed significantly higher scores in SIEDY r scale 2, which explores the relational component of ED. In particular, perceived partner's libido and climax were crucially associated with an impairment of patients' sexual desire. In conclusion, HSD in ED is associated with several biological, psychological, and relational factors that can be simultaneously identified and quantified using the SIEDY r structured interview.
Introduction
Loss of sexual desire is considered the most widespread sexuality-related problem in the general population. 1 The fourth edition of the Diagnostic and Statistical Manual for Mental Disorders (DSM-IV) included hypoactive sexual desire (HSD), defined as persistently or recurrently deficient (or absent) sexual fantasy and desire for sexual activity, leading to marked distress or interpersonal difficulty. 2 In men, HSD is often associated with erectile dysfunction (ED), and may contribute to its pathogenesis.
It is quite clear that severe hyperprolactinemia and hypogonadism can determine HSD in men, and that an appropriate treatment of these conditions can restore sexual desire. [3] [4] [5] [6] However, both disorders have a low prevalence among subjects with ED, [7] [8] [9] and can therefore account only for a small minority of cases of HSD. Many other conditions, including mental disorders, medications, and physical or psychological distress, 1, 3 have been evoked as the possible pathogenetic factors for loss of desire; however, their contribution to the impairment of libido in patients with ED has not been systematically studied so far.
We recently developed and validated a structured interview for identification and quantification of pathogenetic factors of ED. 10 Statistical analysis on the distribution of scores of individual items suggested the inclusion of loss of desire in scale 3 of the interview, together with symptoms related to psychological distress. This seems to suggest that loss of desire could be associated with intrapsychic determinants rather than endocrine diseases.
Hence, the aim of this study is to define psychological and biological correlates of HSD in a sample of patients with ED.
Patients and methods
A consecutive series of 428 patients attending for the first time the Outpatient Clinic for ED of the Andrology Unit of the University of Florence at Careggi Hospital was studied. Patients with mental retardation, or not fluent in Italian, were excluded. Characteristics of the sample are summarized in Table 1 .
Patients were interviewed prior to the beginning of any treatment, and before any specific diagnostic procedures, using the SIEDY r structured interview. 10 This brief, multidimensional instrument designed for the pathogenetic assessment of ED provides scores for organic, marital, and psychopathological factors affecting sexual function, which can be simultaneously present in the same patient. Item #14 of the interview ('Did you have more or less desire to make love in the last 3 months') investigates the patient's loss of desire, using a 0-3 Likert scale. 10 Patients were asked to specify any current pharmacological treatment; drugs listed in Broderick and Foremann 11 were considered capable of interfering with sexual function.
Patients were asked to complete the Middlesex Hospital Questionnaire, modified (MHQ), 12 a brief self-reported questionnaire for the screening of mental disorders, which provides scores for freefloating anxiety, phobic anxiety, obsessive-compulsive traits and symptoms, hysterical traits and symptoms, somatization and depressive symptoms.
All patients underwent a complete physical examination, with measurement of blood pressure (mean of three measurements 5 min apart, in sitting position, with a standard sphygmomanometer), height, weight, and testis volume (Prader orchidometer). Erectile function was investigated using a brief structured interview, which is reported in Appendix A of SIEDY r . 10 Blood samples were drawn in the morning (0730-0930 h), after overnight fast, for determination of blood glucose (by glucose oxidase method, Aeroset Abbott, Rome, Italy) total and HDL cholesterol, and triglyceride (by automated enzymatic colorimetric method; Aeroset Abbott, Rome, Italy), total testosterone, prolactin, FSH, LH, TSH, PSA (by electrochemiluminescent method, Modular Roche, Milan, Italy), and free testosterone (by radioimmunoassay method; Diagnostic Products Corporation, Los Angeles, USA). LDL-cholesterol was not calculated, as some of the patients showed triglyceride levels over In addition, since a normal PGE 1 responsiveness might be present also in patients with arteriogenic ED, 14, 15 penile duplex ultrasound examination was performed before and after PGE 1 intracavernous injection (10 mg). The following parameters were considered: basal peak systolic velocity and acceleration, peak systolic velocity and end diastolic velocity after PGE 1 intracavernous injection (10 mg), and resistance index. 16 Data were expressed as mean7s.d. when normally distributed, and as median (quartiles) for parameters with non-normal distribution. Differences among more than two groups were assessed with one-way factorial ANOVA. Unpaired two-sided Student's t-tests were used for comparison of means of normally distributed parameters; when distribution could be normalized through logarithmic transformation, as in the case of prolactin, the same test was applied to logarithmically transformed data. In all other cases, Mann-Whitney U-test was used for comparisons between groups. Correlations were assessed using Pearson's method or Spearman's method, whenever at least one of parameters had a non-normal distribution. Stepwise multiple linear regression was applied for multivariate analysis, categorizing yes/no parameters as dummy 0/1 variables, whenever appropriate. w 2 test was used for comparison of categorical parameters.
All statistical analysis was performed on SPSS for Windows 10.0.
Results

Aging and loss of sexual desire
Among the patients studied, 94 (22. 8%) reported a mild loss of desire, 53 (12.9%) a moderate reduction of libido, while 19 (4.6%) complained of a complete absence of sexual interest. No significant correlation was found between patients' loss of desire and patients' age, or partners' age (data not shown), and no significant difference in loss of desire was observed comparing patients of different age groups, while a statistically significant (Po0.0001 at ANO-VA) age-dependent loss of libido (as reported by the patient) was observed in the patients' partners ( Figure 1 ).
Endocrine correlates of loss of sexual desire
ANOVA showed a significant (Po0.005) difference of total, free testosterone and prolactin levels among patients with different severities of HSD. Patients reporting an impairment of libido showed significantly lower testosterone levels when compared with the rest of the sample (14.875.6 vs 17.176.5 nmol/l; Po0.005); similar results were obtained when comparing free testosterone in patients with any degree of HSD and in the rest of the sample (45.3715.0 vs 39.6712.6 pmol/l; Po0.005). Prolactin levels were significantly higher only in patients with moderate or severe HSD in comparison with the rest of the sample (169 mU/l (120-245) vs 150 mU/l (110-229); Po0.05). Of the 56 hypogonadal patients (testosterone o10 nmol/l), 26 reported a reduction of sexual desire, that was moderate or severe in 11 (46.4 and 19.6%, respectively, vs 37.1 and 14.5%, respectively, in the rest of the sample; P ¼ NS). Hence, patients with HSD were not most frequently defined as hypogonadic than the rest of the sample. Eight patients resulted to be affected by severe hyperprolactinemia (prolactin4700 mU/l); four of them had a prolactinoma (three macro and one microadenoma), three a drug-related hyperprolactinemia, and one a hyperprolactinemia of unknown origin. Among patients with severe hyperprolactinemia, seven reported impaired desire of any severity, and five moderate or severe loss of desire (87.5 and 62.5%, respectively, vs 38.1 and 14.5%, respectively, in the rest of the sample; both Po0.01). In these patients, total testosterone was not statistically different from the rest of the sample.
No significant correlation of HSD was observed with circulating FSH (r ¼ 0.04), LH (r ¼ 0.04), TSH (r ¼ 0.06), and testis volume (r ¼ À0.08; all P ¼ NS).
Other biological correlates of loss of sexual desire PSA, blood pressure, lipid profile, glycemia, and parameters derived from echo color doppler 
examination did not show any significant correlation with sexual desire (data not shown). No differences in loss of desire were observed between patients with and without a positive response to PGE1 test, and no significant correlation was observed with the ability to obtain and maintain erection. On the other hand, a significant correlation (r ¼ 0.20; Po0.0001) was observed between the loss of desire and the score of item #13 of SIEDY r , exploring reported nocturnal/morning erection.
HSD was reported by 43 of the 74 patients taking medication capable of interfering with sexual function, and by 125 of the remaining 354 patients (58.1 vs 35.3%; Po0.01).
Psycho-relational correlates of loss of sexual desire
Of the 21 patients who reported current or previous mental disorders, nine (42.9%) showed a moderate or severe loss of desire, while in the rest of the sample only 65 out of 407 patients (15.9%) complained such symptom. Considering that many psychotropic drugs are among those capable of interfering with sexual desire, 11 use of medications and reported mental disorders were analysed as the putative determinants of HSD in a multivariate analysis; both factors were significantly associated with HSD (B7SE, 0.5770.20 and 0.3070.11 for use of medications and mental disorders, respectively; both Po0.005). (Figure 2 ), but not MHQ-F and MHQ-E (data not shown), were significantly (Po0.05) different at ANOVA among patients with different severity of loss of desire. A mild impairment of sexual interest was associated with a significant (Po0.01) increase in MHQ-A, MHQ-O, MHQ-S, and MHQ-D scores when compared with patients without any loss of desire. A more severe impairment of desire was not associated with further increases in MHQ scores.
Scores of MHQ-A, MHQ-O, MHQ-S, and MHQ-D
Patients with any degree of loss of desire showed higher scores on items of SIEDY r scale 3, which explores the psychological components of ED. In particular, patients with HSD reported significantly (Po0.01) greater stress at work (item 3), and greater disturbances of relationships at home (item 11; data not shown). Correlations of scores of scale 3 of SIEDY r with loss of desire were not explored, as impairment of sexual interest is one of the components of scale 3. ANOVA showed a significant (Po0.005) difference in the scores of SIEDY r scale 2, which explores the relational component of ED, among patients with different severities of loss of desire. Patients reporting HSD showed a significantly higher scale 2 scores when compared to the rest of the sample (2 (0-4) vs 1 (0-3); Po0.005). A significant correlation of loss of sexual desire with scale 2 of SIEDY r was observed (r ¼ 0.16; Po0.005). Of the items composing scale 2 of SIEDY r , the patient's loss of desire showed a significant correlation with items # 7 (partner's diseases interfering with sexual activity), 8 (partner's libido), and 9 (partner's climax), with r ¼ 0.14, 0.10, and 0.15, respectively (all Po0.05), but not with item #10 (partner's menopausal symptoms).
Relative impact of different components on impairment of sexual desire
In order to assess the impact of psycho-relational and biological parameters on HSD, separate step- 
Discussion
The estimated prevalence of loss of sexual desire in the general male population is around 15%. 1 In the present sample, over 40% of patients with ED reported some form of impaired libido. This suggests a possible causal relationship between HSD and ED, or the existence of the underlying common pathogenic factors, at least in part of the cases. However, the majority of the patients studied, who were affected by ED, did not report any impairment of sexual desire. In fact, no significant correlation of sexual desire with subjective and objective parameters of erectile activity was observed, showing that ED and HSD are not necessarily associated. In particular, we did not find any significant association of loss of libido with responsiveness to PGE 1 or with any of the multiple vascular parameters derived from duplex sonography of penile vessels. However, we did find a negative relationship between the entity of loss of sexual desire and the number of self-reported episodes of spontaneous early morning/nocturnal erections. This latter symptom has been classically related to an organic more than to a psychogenic origin of ED. [17] [18] [19] [20] In addition, we previously reported that it aggregates with other organic-related items in SIEDY r scale 1. 10 However, no association of HSD was found with a history of diabetes mellitus, dyslipidemia, hypertension, smoking, cardiovascular, and thyroid diseases. In our series, 13% of the patients with ED were hypogonadal. Similar figures have been reported previously. 7, 9, 21 However, loss of sexual interest was not associated with hypogonadism, although patients with decreased libido had lower levels of total testosterone than the rest of the sample. This further indicates that testosterone could be an important but not an essential determinant of sexual desire. 3 In agreement with previous reports, 9,21-23 a minority (1.9%) of our ED patients showed severe hyperprolactinemia (4700 mU/ml), which in half of them was due to pituitary tumor. Interestingly, almost all (87%) of the hyperprolactinemic patients reported impairment in sexual desire, which was sustained in the large majority. Hence, prolactin could be a relevant hormonal factor regulating sexual desire, although hyperprolactinemia is a relatively remote diagnosis in ED patients. It is still unclear how elevated prolactin levels may affect libido. Although severe hyperprolactinemia is usually associated with hypogonadism, a direct effect of prolactin on sexual desire was also hypothesized, 8 because in hyperprolactinemic patients testosterone treatment was not able to restore libido, 24 while prolactinlowering drugs were very effective. 5, 6 Interestingly, in hyperprolactinemic patients, testosterone was in the normal range. It is possible, therefore, to miss a significant hyperprolactinemia if only serum testosterone is measured during the initial screening, in particular in ED patients complaining loss of libido as previously reported. 23 Patients reporting a history of psychiatric disorders complained HSD more frequently than the rest of the sample. Similarly, patients taking medications known to interfere with sexual function 11 reported HSD more often. Many psychotropic drugs are capable of reducing sexual desire; however, multivariate analysis showed that both mental disorders and medications were independently associated with reduced desire. It should be observed that self-report of psychiatric diseases underestimates the actual prevalence of mental disorders, which has been reported to be much higher in patients with ED. 25 However, the relationship of loss of desire with psychopathological parameters was confirmed when considering correlation with the scores of the MHQ psychometric test, which was designed for the assessment of even mild psychopathological symptoms in a nonpsychiatric setting. 12 Loss of sexual desire is recognized as one of the symptoms of depressive disorders; therefore, the finding of higher MHQ scores of the depressive symptom scale in patients with HSD comes as no surprise. In addition, a relevant association of HSD with anxiety-related symptoms, such as somatization, was observed. The association of somatization with loss of libido cannot be entirely accounted for by the coexistence of depressive symptoms; 26 in fact, it is confirmed at multivariate analysis after adjustment for depression. Somatization is one of the expressions of chronic anxiety, which can be increased in many euthymic subjects. The present data suggest that HSD could represent one of the many expressions of somatization, which is known to affect many other physiologic functions such as gastrointestinal and cardiovascular functions.
The higher scores of SIEDY r scale 2 in patients with HSD confirm the relevant role of relationship with partner in the modulation of sexual desire. 27 An accurate assessment of the features of relationship with the partner is an important area of ED, which should be explored in clinical practice. 10 In
Psycho-biological correlates of hypoactive sexual desire G Corona et al particular, the partner's libido and climax could reinforce the patient's sexual desire. It could be speculated that female's desire and satisfaction are perceived by men as a confirmation of their male sexual identity. It should be noted that, in the present study, the partners' libido and climax were reported by the patients, and they could differ from that perceived by the partners. However, the patient's perceptions of the partner's attitudes could be even more important as determinants of male desire than the woman's actual libido and climax. It should also be considered that loss of sexual desire of the partner could prevent subjects with ED from medical consultation; therefore, patients with partners with impaired libido could be underrepresented in the present sample. Although loss of sexual desire is generally regarded as one of the main clinical manifestations of the so-called andropause, 28 in our sample, no association between aging and loss of sexual desire was observed. This finding is in agreement with a previous cross-sectional study on impotent men and aging. 29 However, it should be recognized that this study, as well as the previous one, 29 was performed on a clinical sample of self-referred patients, wishing to improve their erectile performance; some elderly subjects could consider loss of libido as a normal element of aging, not deserving medical care. 30, 31 Therefore, elderly patients with loss of desire may consult less than younger subjects with similar characteristics. On the other hand, a marked reduction of partner's desire, as reported by the patients, was observed with the advancing age of the partner. These results would suggest that aging interferes with sexual desire to a greater extent in women than in men; however, particular caution should be used in the interpretation of data on the partner's desire, which are reported by the patients, and not directly investigated.
In conclusion, reduction of sexual desire in patients with ED appears to be associated with a number of biological, psychological, and relational factors. Among biological factors, hyperprolactinemia could be more relevant than hypogonadism, while vascular and neurological disturbances do not seem to be associated with impairment of libido. Psychological factors related to reduced sexual desire include both depressed mood and symptoms of anxiety. Finally, features of relationship with the partner, including perceived partner's libido and climax, might play a crucial role in the impairment of patients' sexual desire.
